O
NKTR icon

OppenheimerFunds’s Nektar Therapeutics NKTR Stock Holding History

OppenheimerFunds’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$581M Sell
1,153,526
-2
-0% -$1.19K 0.72% 27
2018
Q4 		$569M Buy
1,153,528
+353,377
+44% +$213M 0.81% 18
2018
Q3 		$732M Buy
800,151
+29,432
+4% +$25.1M 0.85% 15
2018
Q2 		$565M Buy
770,719
+56,351
+8% +$65M 0.67% 23
2018
Q1 		$1.14B Sell
714,368
-259,270
-27% -$334M 1.42% 5
2017
Q4 		$872M Sell
973,638
-677,844
-41% -$401M 1.05% 8
2017
Q3 		$595M Sell
1,651,482
-32,333
-2% -$10.1M 0.73% 19
2017
Q2 		$494M Buy
1,683,815
+83,094
+5% +$24M 0.61% 30
2017
Q1 		$564M Sell
1,600,721
-66,500
-4% -$14.9M 0.68% 18
2016
Q4 		$307M Buy
1,667,221
+247
+0% +$50.2K 0.39% 68
2016
Q3 		$430M Sell
1,666,974
-66,716
-4% -$17.2M 0.54% 33
2016
Q2 		$370M Sell
1,733,690
-161
-0% -$36K 0.49% 47
2016
Q1 		$358M Buy
1,733,851
+293
+0% +$56.3K 0.47% 51
2015
Q4 		$438M Sell
1,733,558
-26,442
-2% -$5.44M 0.56% 39
2015
Q3 		$289M Buy
1,760,000
+26,667
+2% +$4.72M 0.39% 66
2015
Q2 		$325M Hold
1,733,333
– – 0.37% 65
2015
Q1 		$286M Buy
1,733,333
+120,000
+7% +$24.7M 0.32% 88
2014
Q4 		$375M Sell
1,613,333
-13,334
-0.8% -$2.85M 0.42% 60
2014
Q3 		$295M Hold
1,626,667
– – 0.32% 80
2014
Q2 		$313M Hold
1,626,667
– – 0.35% 72
2014
Q1 		$296M Buy
1,626,667
+93,334
+6% +$18.5M 0.35% 74
2013
Q4 		$261M Sell
1,533,333
-1,533,334
-50% -$247M 0.32% 79
2013
Q3 		$481M Buy
3,066,667
+1,553,334
+103% +$287M 0.32% 86
2013
Q2 		$262M Buy
+1,513,333
New +$232M 0.38% 61

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

OppenheimerFunds's NKTR Position: Q1 2019 in Review

OppenheimerFunds reduced its Nektar Therapeutics (NKTR) stake by 0% in Q1 2019, selling an estimated $1.19K and leaving 1,153,526 shares worth $581M. The position accounts for 0.72% of the portfolio, ranked #27.

OppenheimerFunds first reported a position in NKTR in Q2 2013 and has held it in 24 quarters since. The position peaked at $1.14B in Q1 2018. 350 funds tracked by Wall St. Rank hold NKTR as of Q1 2019.

  • OppenheimerFunds held 1,153,526 shares of Nektar Therapeutics worth $581M as of Q1 2019.
  • OppenheimerFunds sold 2 Nektar Therapeutics shares in Q1 2019, an estimated $1.19K.
  • Nektar Therapeutics made up 0.72% of OppenheimerFunds's portfolio in Q1 2019, its #27 holding.
  • OppenheimerFunds first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 24 quarters since.
  • OppenheimerFunds's Nektar Therapeutics position peaked at $1.14B in Q1 2018.
  • 350 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2019.

Based on OppenheimerFunds's 13F filing for Q1 2019, filed 13 May 2019.